Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0143-0406 in Type 1 Diabetes
NCT02612844Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2015
- Primary completion
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0143-0406 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events. Started Nov 2015; status: completed.
02
Drugs
NNC0143-0406
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02612844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612844.